|
1
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sidwell RW, Huffman JH, Khare GP, Allem
LB, Witkowski JT and Robins RK: Broad-spectrum antiviral activity
of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.
Science. 177:705–706. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kohli A, Shaffer A, Sherman A and Kottilil
S: Treatment of hepatitis C: A systematic review. JAMA.
312:631–640. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kentsis A, Topisirovic I, Culjkovic B,
Shao L and Borden KL: Ribavirin suppresses eIF4E-mediated oncogenic
transformation by physical mimicry of the 7-methyl guanosine mRNA
cap. Proc Natl Acad Sci USA. 101:18105–18110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Assouline S, Culjkovic B, Cocolakis E,
Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH
Jr and Borden KL: Molecular targeting of the oncogene eIF4E in
acute myeloid leukemia (AML): A proof-of-principle clinical trial
with ribavirin. Blood. 114:257–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borden KL and Culjkovic-Kraljacic B:
Ribavirin as an anti-cancer therapy: Acute myeloid leukemia and
beyond? Leuk Lymphoma. 51:1805–1815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ogino A, Sano E, Ochiai Y, Yamamuro S,
Tashiro S, Yachi K, Ohta T, Fukushima T, Okamoto Y, Tsumoto K, et
al: Efficacy of ribavirin against malignant glioma cell lines.
Oncol Lett. 8:2469–2474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De la Cruz-Hernandez E, Medina-Franco JL,
Trujillo J, Chavez-Blanco A, Dominguez-Gomez G, Perez-Cardenas E,
Gonzalez-Fierro A, Taja-Chayeb L and Dueñas-Gonzalez A: Ribavirin
as a tri-targeted antitumor repositioned drug. Oncol Rep.
33:2384–2392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Volpin F, Casaos J, Sesen J, Mangraviti A,
Choi J, Gorelick N, Frieche J, Lott T, Felder R, Scotland SJ, et
al: Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma
therapeutic. Oncogene. 36:3037–3047. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ochiai Y, Sano E, Okamoto Y, Yoshimura S,
Makita K, Yamamuro S, Ohta T, Ogino A, Tadakuma H, Ueda T, et al:
Efficacy of ribavirin against malignant glioma cell lines:
Follow-up study. Oncol Rep. 39:537–544. 2018.PubMed/NCBI
|
|
11
|
Casaos J, Huq S, Lott T, Felder R, Choi J,
Gorelick N, Peters M, Xia Y, Maxwell R, Zhao T, et al: Ribavirin as
a potential therapeutic for atypical teratoid/rhabdoid tumors.
Oncotarget. 9:8054–8067. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saito R, Mizuno M, Hatano M, Kumabe T,
Yoshimoto T and Yoshida J: Two different mechanisms of apoptosis
resistance observed in interferon-β induced apoptosis of human
glioma cells. J Neurooncol. 67:273–280. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshino A, Katayama Y, Yokoyama T,
Watanabe T, Ogino A, Ota T, Komine C, Fukushima T and Kusama K:
Therapeutic implication of interferon regulatory factor 1 (IRF-1)
and IRF-2 in diffusely infiltrating astrocytomas (DIA): Response to
(IFN)-beta in glioblastoma cells and prognostic value for DIA. J
Neurooncol. 74:249–260. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vannucchi S, Chiantore MV, Mangino G,
Percario ZA, Affabris E, Fiorucci G and Romeo G: Perspective in
biomolecular therapeutic intervention in cancer: From the early to
the new strategies with type 1 interferons. Curr Med Chem.
14:667–679. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoshino A, Tashiro S, Ogino A, Yachi K,
Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Sano E and
Tsumoto K: Gene expression profiles predicting the response to
IFN-β and a combination of temozolomide and IFN-β in malignant
gliomas. Int J Oncol. 39:529–542. 2011.PubMed/NCBI
|
|
16
|
Yoshida J, Kajita Y, Wakabayashi T and
Sugita K: Long-term follow-up results of 175 patients with
malignant glioma: Importance of radical tumor resection and
post-operative adjuvant therapy with interferon, ACNU and
radiation. Acta Neurochir. 127:55–59. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Natsume A, Ishii D, Wakabayashi T, Tsuno
T, Hatano H, Mizuno M and Yoshida J: IFN-beta down-regulates the
expression of DNA repair gene MGMT and sensitizes resistant glioma
cells to temozolomide. Cancer Res. 65:7573–7579. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park JA, Joe YA, Kim TG and Hong YK:
Potentiation of anti-glioma effect with combined temozolomide and
interferon-beta. Oncol Rep. 16:1253–1260. 2006.PubMed/NCBI
|
|
19
|
Yoshino A, Ogino A, Yachi K, Ohta T,
Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N and Sano
E: Effect of IFN-beta on human glioma cell lines with temozolomide
resistance. Int J Oncol. 35:139–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schlosser SF, Schuler M, Berg CP, Lauber
K, Schulze-Osthoff K, Schmahl FW and Wesselborg S: Ribavirin and
alpha interferon enhance death receptor-mediated apoptosis and
caspase activation in human hepatoma cells. Antimicrob Agents
Chemother. 47:1912–1921. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Teng L, Ding D, Chen Y, Dai H, Liu G, Qiao
Z and An R: Anti-tumor effect of ribavirin in combination with
interferon-α on renal cell carcinoma cell lines in vitro. Cancer
Cell Int. 14:632014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshino A, Ogino A, Yachi K, Ohta T,
Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E
and Tsumoto K: Gene expression profiling predicts response to
temozolomide in malignant gliomas. Int J Oncol. 36:1367–1377. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wischhusen J, Naumann U, Ohgaki H,
Rastinejad F and Weller M: CP-31398, a novel p53-stabilizing agent,
induces p53-dependent and p53-independent glioma cell death.
Oncogene. 22:8233–8245. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ostermann S, Csajka C, Buclin T, Leyvraz
S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal
fluid population pharmacokinetics of temozolomide in malignant
glioma patients. Clin Cancer Res. 10:3728–3736. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Naik GS and Tyagi MG: A pharmacological
profile of ribavirin and monitoring of its plasma concentration in
chronic hepatitis C infection. J Clin Exp Hepatol. 2:42–54. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren H, Tan X, Dong Y, Giese A, Chou TC,
Rainov N and Yang B: Differential effect of imatinib and synergism
of combination treatment with chemotherapeutic agents in malignant
glioma cells. Basic Clin Pharmacol Toxicol. 104:241–252. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kast RE, Skuli N, Cos S, Karpel-Massler G,
Shiozawa Y, Goshen R and Halatsch ME: The ABC7 regimen: A new
approach to metastatic breast cancer using seven common drugs to
inhibit epithelial-to-mesenchymal transition and augment
capecitabine efficacy. Breast Cancer. 9:495–514. 2017.PubMed/NCBI
|
|
29
|
Stewart WE, Gosser JB and Lockart RZ Jr:
Priming: A nonantiviral function of interferon. J Virol. 7:792–801.
1971. View Article : Google Scholar : PubMed/NCBI
|
